Since proinflammatory cytokines including IL-1β, IL-6, and TNF-α play a critical role in the immunopathogenesis of RA [19,20] and increased PADIs activities have been documented in patients with RA [21], targeting PADIs would be a novel strategy for RA treatment. This evidence concerns the gene IL6 and rheumatoid arthritis.